FTRP earnings

Completed corporate reorganization, separating the Field Trip Discovery and Field Trip Health divisions into two separate companies.Field Trip Discovery renamed Reunion Neuroscience Inc. ("Reunion" or the "Company"), and will remain listed on the NASDAQ Stock Market and Toronto Stock Exchange under new ticker symbol "REUN".Field Trip Health renamed Field Trip Health & Wellness Ltd. ("Field Trip H&W") and has received listing approval from the Toronto Stock Exchange Venture under new ticker symbol "FTHW".First day of trading for both Reunion and Field Trip H&W is August 17, 2022.On July 21, 2022, announced successful first dosings in the Company's Phase 1 Clinical Study of its first novel psy

TORONTO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX:FTRP, NASDAQ:FTRP) ("Field Trip" or the "Company"), a global leader in the development and delivery of psychedelic therapies, announced today that it plans to release financial results for its fiscal 2023 first quarter for the three-month period ended June 30, 2022, after market close on Monday, August 15, 2022. The Company will conduct a conference call and webcast to discuss its results the following morning, Tuesday, August 16, 2022 at 8:30 a.m. ET. To access the call, please dial 1-877-407-9716 (within the U.S.) or 1-201-493-6779 (outside the U.S.) and provide conference ID 13731900. A live webcast of the conferenc

Completed strategic review and announced intention to separate the Field Trip Discovery and Field Trip Health divisions into two independent public companies.Earned patient services revenues of $1.7 million in fiscal fourth quarter, an increase of 26.7% over the prior quarter and 228% year over year. Full year patient services revenue was $4.9 million, up from $0.96 million in the same period of the prior year.At March 31, 2022, Field Trip had approximately $63.7 million in unrestricted cash and cash equivalents.On April 5, 2022, granted U.S Patent for the first novel psychedelic molecule in development, molecule FT-104, for exclusive rights for the composition of matter, use and manufacturi

TORONTO, June 22, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX:FTRP, FTRP.WT, NASDAQ:FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that it plans to release financial results for its fiscal fourth quarter and full year ended March 31, 2022, after market close on Wednesday, June 29, 2022. The Company will conduct a conference call and webcast to discuss its results the following morning, Thursday, June 30, 2022 at 8:30 a.m. ET. To access the call, please dial 1-877-407-9716 (within the U.S.) or 1-201-493-6779 (outside the U.S.) and provide conference ID 13730739. A live webcast of the conference call can be accessed v

Transaction will create two distinct emerging leaders in the psychedelics industry, one providing personalized care and the other developing next generation psychedelic therapies. Shareholders of Field Trip will receive shares of each company. Company to host a conference call on Friday, April 29, 2022 at 8:30 a.m. ET. TORONTO, April 28, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX:FTRP, FTRP.WT, NASDAQ:FTRP) (the "Company"), a global leader in the development and delivery of psychedelic therapies, announced today that it has received unanimous board approval to complete a reorganization that will result in the separation of its Field Trip Discovery and Field Trip Health divisio

Earned patient services revenues of $1,360,811, an increase of 50% over the prior quarter and 330% year over year.At December 31, 2021, Field Trip had approximately $74.5 million in unrestricted cash and cash equivalents and short-term investments.Received Notice of Allowance for US Patent Application Covering FT-104 (Isoprocin Glutarate), a more soluble, stable prodrug form of the psychedelic molecule 4-HO-DiPT.Launched Site Management Organization Services ("SMO") and appointed Stéphan Côté as Head of Quality to lead the program which enables companies and researchers developing psychedelic therapies to use Field Trip's world class facilities, and expertly trained medical and therapy teams

TORONTO, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX:FTRP, FTRP.WT, NASDAQ:FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that it plans to release financial results for the fiscal third quarter ended December 31, 2021, after market close on Tuesday, February 15, 2022. The Company will conduct a conference call and webcast to discuss its results the following morning, Wednesday, February 16, 2022 at 8:30am ET. To access the call, please dial 1-877-407-9716 (within the U.S.) or 1-201-493-6779 (outside the U.S.) and provide conference ID 13726364. A live webcast of the conference call can be accessed via t

Announced plans to advance FT-104, its novel psychedelic compound, to clinic for Treatment-Resistant Depression and Postpartum Depression as the lead indications.Initiated a new pipeline research program focused on discovering novel psychedelics with a reduced cardiovascular risk profile compared to classic psychedelics (the "FT-200 Group") and filed a provisional patent in connection to the composition of matter for the first molecule identified in the FT-200 Group.Continued to invest in best-in-class clinical infrastructure, with nine clinics currently in operation and nine locations under construction or about to commence construction.Commenced trading on the NASDAQ Global Select Market (

TORONTO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX:FTRP, FTRP.WT, NASDAQ:FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that it plans to release financial results for the fiscal second quarter ended September 30, 2021, after market close on Monday, November 15, 2021. The Company will conduct a conference call and webcast to discuss its results the following morning, Tuesday, November 16 at 8:30 am ET. To access the call, please dial 1-877-407-9716 (within the U.S.) or 1-201-493-6779 (outside the U.S.) and provide conference ID 13724604. A live webcast of the conference call can be accessed via the Events

At June 30, 2021 had approximately $100 million in unrestricted cash and cash equivalents, funds held in trust and short-term investmentsDevelopment of FT-104, a novel psychedelic molecule with pending patents, continues to progress with GMP production achievedThe Company remains on track to meet milestone of 20 sites open or under construction by December 2021 TORONTO, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX:FTRP, FTRP.WT, NASDAQ:FTRP) ("Field Trip"), a leader in the development and delivery of psychedelic therapies, reported its fiscal first quarter 2022 results for the three months ended June 30, 2021. All results are reported under International Financial Rep

TORONTO, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX:FTRP, FTRP.WT, NASDAQ:FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that it plans to release financial results for its first fiscal quarter ended June 30, 2021, after market close on Monday, August 16, 2021. The Company will conduct a conference call and webcast to review its results the following day, Tuesday, August 17 at 8:30 am ET. To access the call, please dial 1-877-407-9716 or 1-201-493-6779 and provide conference ID 13722164. A live webcast of the conference call can be accessed via the Events and Presentations section of the Field Trip Health I